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failure. We would be happy to collaborate with Dr. Stein to study
“erratic sinus rhythm” with a specific research software, because the
analogic tape of the ambulatory electrocardiograms of our patients
is still available. However, from a practical standpoint, we consider
that an important issue of our article is that our results were
obtained with a commercially available Holter monitoring system,
and with demonstration that SDNN, a simple and reproducible
measurement of HRV, is probably the most powerful for risk
stratification. These findings may have more direct implications for
identifying patients at risk and may guide subsequent investiga-
tions and therapy, either on an individual basis or as part of a
controlled clinical trial.
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Carvedilol in Class IV Heart Failure
Macdonald et al. (1) have reported favorably on the use of
carvedilol in patients with New York Heart Association functional
class IV heart failure. However, no mortality figures were stated.
Table 3, “Nonfatal Adverse Events,” indicates that 27 of 63
patients in functional class IV experienced adverse events, most
commonly worsening heart failure. But no information on the
number of deaths in the 63 patients is reported. On page 933,
“Actuarial Survival,” the statement is made that “the 1-year
mortality of 16 6 5% in this patient group treated with carvedilol
compares favorably with the mortality reported for similar patient
groups in other studies.” However, patients in functional class IV
heart failure with certain unfavorable characteristics were excluded.
The following were the exclusion criteria: cardiogenic shock,
intractable pulmonary or systemic edema, heart failure requiring
intravenous inotropic or mechanical support, bradycardia with
heart rate ,50 beats/min, systemic hypotension with blood pres-
sure ,80/50 mm Hg or chronic air flow limitation with evidence
of $20% reversibility in airway obstruction in response to inhaled
salbutamol. It would seem reasonable to expect that with these very
sick patients excluded from the treatment group, the mortality
figures in the remainder receiving carvedilol would be clearly
favorable in comparison to any control group, if carvedilol were
indeed beneficial.
Because adverse events with carvedilol therapy usually occur
early in the treatment course, it would be important to know not
only how many of the treated patients in functional class IV died,
but also the duration of their treatment before death. One would
anticipate that the deaths occurred early.
Additional data on the survival of patients in functional class IV
heart failure treated with carvedilol are clearly needed.
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We thank Dr. Hoffman for his comments. As stated in our report
(1), the actuarial survival rate for patients in New York Heart
Association functional class IV heart failure at one year was 84%
and the one-year mortality rate was 16%. Overall, 10 patients in
functional class IV died within the first year after commencement
of carvedilol. As shown in Figure 1 (page 926), the deaths occurred
throughout the year, with no apparent clustering at the time of
initiation or titration of carvedilol. Causes of death were judged to
be progressive heart failure in five patients and sudden cardiac
death in five patients. All five patients who died suddenly were
taking carvedilol at the time of their death and had been treated for
6, 74, 96, 127 and 203 days, respectively. Deaths from progressive
heart failure occurred at days 41, 46, 142, 153 and 259. Carvedilol
was withdrawn before death in all five patients who subsequently
died of progressive heart failure. The reason for withdrawal in all
five patients was worsening heart failure, and the period between
carvedilol withdrawal and death ranged from 23 to 228 days.
We recognize that not all patients in functional class IV heart
failure referred to our institution were challenged with carvedilol;
however, we believe our patients are comparable to those in class
IV included in the other studies that we have cited. For instance,
in the CONSENSUS Study (26) in which the 1-year mortality
rate for enalapril was ;40%, all patients had to be stable on
medical therapy for 2 weeks before trial entry. Patients on
intravenous inotropic therapy and mechanical support were ex-
cluded. Similarly, in the study of Lee and Packer (19), only
patients with stable chronic functional class IV heart failure were
included. The one-year mortality rate in this study for patients
receiving angiotensin-converting enzyme inhibitors was ;50%.
As stated in the Discussion of our report, we can only speculate
on the impact of carvedilol on survival; however, we believe that a
one-year mortality rate of only 16% compares favorably with
historic reports such as those cited. The recently published Cardiac
Insufficiency Bisoprolol Study (CIBIS-II) (2) provides the stron-
gest evidence to date that the beneficial effects of beta-blockers in
heart failure extend to patients who are in functional class IV at
baseline. Seventeen percent of 2,647 patients entered into
CIBIS-II were in functional class IV at baseline. Active treatment
with bisoprolol reduced mortality by 34% as compared with
placebo, with no significant difference between class III and class
IV. Patients with severe functional class IV heart failure and recent
instability were excluded from CIBIS-II, as in our study.
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